María del Monte-Millan

Mrs. María del Monte-Millan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2019 in BMC Genomics
Verified
Journal Article
Open access
PDF file
APAntonio Picornell
Antonio Picornell
IEI. Echavarria
I. Echavarria
ECEnrique Luis Álvarez Castillo
Enrique Luis Álvarez Castillo
SLSara López-Taruella
Sara López-Taruella
YJY. Jerez
Y. Jerez
MMMiguel Martin
Miguel Martin
Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular. The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80. In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method.


11 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMiguel Martin
Miguel Martin
RYRachel Yoder
Rachel Yoder
RSRoberto Salgado
Roberto Salgado
MMMaría del Monte-Millan
María del Monte-Millan
ECEnrique Luis Álvarez Castillo
Enrique Luis Álvarez Castillo
PSPriyanka Sharma
Priyanka Sharma
Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known. Experimental Design: This is a pooled analysis of two studies where patients with stage I (T>1 cm)–III TNBC received carboplatin (AUC 6) plus docetaxel (75 mg/m2; CbD) NAC. sTILs were evaluated centrally on pre-treatment hematoxylin and eosin slides using standard criteria. Cox regression analysis was used to examine the effect of variables on event-free survival (EFS) and overall survival (OS). Results: Among 474 patients, 44% had node-positive disease. Median sTILs were 5% (range, 1%–95%), and 32% of patients had ≥30% sTILs. pCR rate was 51%. On multivariable analysis, T stage (OR, 2.08; P = 0.007), nodal status (OR, 1.64; P = 0.035), and sTILs (OR, 1.10; P = 0.011) were associated with pCR. On multivariate analysis, nodal status (HR, 0.46; P = 0.008), pCR (HR, 0.20; P < 0.001), and sTILs (HR, 0.95; P = 0.049) were associated with OS. At 30% cut-point, sTILs stratified outcomes in stage III disease, with 5-year OS 86% versus 57% in ≥30% versus <30% sTILs (HR, 0.29; P = 0.014), and numeric trend in stage II, with 5-year OS 93% versus 89% in ≥30% versus <30% sTILs (HR, 0.55; P = 0.179). Among stage II–III patients with pCR, EFS was better in those with ≥30% sTILs (HR, 0.16; P, 0.047). Conclusions: sTILs density was an independent predictor of OS beyond clinicopathologic features and pathologic response in patients with TNBC treated with anthracycline-free CbD chemotherapy. Notably, sTILs density stratified outcomes beyond tumor–node–metastasis (TNM) stage and pathologic response. These findings highlight the role of sTILs in patient selection and stratification for neo/adjuvant escalation and de-escalation strategies.

13 February 2025 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
RMRita A. Mukhtar
Rita A. Mukhtar
SGSoumya Gottipati
Soumya Gottipati
CYChristina Yau
Christina Yau
SLSara López-Taruella
Sara López-Taruella
HEHelena Earl
Helena Earl
WSW. Fraser Symmans
W. Fraser Symmans
Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed in ILC and non-ILC with mixed effect Cox models and multivariable analyses. Recursive partitioning was used in an exploratory model to stratify prognosis by RCB components. Of 5106 patients, the diagnosis was ILC in 216 and non-ILC in 4890. Increased RCB index was associated with worse EFS in both ILC and non-ILC (p = 0.002 and p < 0.001, respectively) and remained prognostic when stratified by receptor subtype and adjusted for age, grade, T category, and nodal status. Recursive partitioning demonstrated residual invasive cancer cellularity as most prognostic in ILC. These results underscore the utility of RCB for evaluating NAC response in those with ILC.

2 July 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
SSShane Stecklein
Shane Stecklein
MMMiguel Martin
Miguel Martin
GVGuillermo Villacampa
Guillermo Villacampa
MMMaría del Monte-Millan
María del Monte-Millan
RYRachel Yoder
Rachel Yoder
PSPriyanka Sharma
Priyanka Sharma
Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these 2 biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.

8 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JAJavier Soto Alsar
Javier Soto Alsar
CPCoral Polo
Coral Polo
ECEnrique Luis Álvarez Castillo
Enrique Luis Álvarez Castillo
MMMaría del Monte-Millan
María del Monte-Millan
NANatalia Gutiérrez Alonso
Natalia Gutiérrez Alonso
PAPilar García Alfonso
Pilar García Alfonso
Background/Objectives: BRAF-mutated (BRAFmut) colorectal cancer (CRC) is associated with a poor prognosis. In the metastatic setting, the role of metastasectomy in this subgroup remains controversial. However, treatment-induced molecular changes may help identify patients who are more likely to benefit from surgical resection of metastatic disease. Methods: A case-control study was conducted involving 14 patients with metastatic CRC, including 7 with BRAF-mutated tumors (case group) and 7 with tumors that were wild type for both RAS or BRAF (control group). Whole-exome sequencing (WES) was performed on FFPE tissue samples obtained before and after systemic therapy. All patients subsequently underwent surgical resection of metastatic lesions. Patients were matched according to primary tumor location (left- vs right-sided) and the site of metastasectomy (liver or peritoneal metastases). Results: Most patients underwent surgical resection of liver metastases (57%), followed by resection of peritoneal metastases (43%). All patients received fluoropyrimidine-based chemotherapy (capecitabine or 5-fluorouracil) in combination with oxaliplatin, and 36% also received irinotecan In addition, 64% received anti-angiogenic therapy (bevacizumab or aflibercept) and 14% received panitumumab. Distinct patterns of post-treatment mutational gain or loss were observed between the Case and Control groups. Furthermore, the profiles of altered genes differed according to metastatic site, primary tumor sidedness, and treatment regimen. No significant differences in overall survival or event-free survival were observed between the two groups. Conclusions: The mutational landscape of mCRC is dynamic rather than static, evolving in response to systemic therapy, the metastatic microenvironment, and the underlying molecular background. These findings support the potential clinical value of incorporating longitudinal genomic monitoring into therapeutic decision-making to identify treatment-induced evolutionary changes and optimize systemic treatment strategies.